The 10-second takeaway
For the quarter ended March 31 (Q2), Avanir Pharmaceuticals beat slightly on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share dropped.
Gross margins dropped, operating margins increased, net margins grew.
Avanir Pharmaceuticals chalked up revenue of $17.4 million. The six analysts polled by S&P Capital IQ predicted revenue of $17.2 million on the same basis. GAAP reported sales were 74% higher than the prior-year quarter's $10.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.12. The five earnings estimates compiled by S&P Capital IQ forecast -$0.09 per share. GAAP EPS were -$0.12 for Q2 against -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.2%, 50 basis points worse than the prior-year quarter. Operating margin was -88.8%, much better than the prior-year quarter. Net margin was -94.8%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $19.4 million. On the bottom line, the average EPS estimate is -$0.07.
Next year's average estimate for revenue is $83.5 million. The average EPS estimate is -$0.23.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 182 members out of 243 rating the stock outperform, and 61 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Avanir Pharmaceuticals a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.60.
- Add Avanir Pharmaceuticals to My Watchlist.